Volume 5 Supplement 1
Improving potency of Chlamydia trachomatis major outer membrane protein muli-epitope DNA vaccine by fusion with human papillomavirues 6b L1
© Xu et al; licensee BioMed Central Ltd. 2011
Published: 10 January 2011
Effective adjuvants are needed to design effective vaccines against Chlamydia trachomatis (Ct). The aim of this study was to observe the immune response stimulated by inoculation of a DNA vaccine encoding a fusion protein comprising multiple Ct major outer membrane protein (MOMP) epitopes and human papillomavirus 6b L1 (HPV 6b L1) as the basis for designing a novel DNA vaccine against genital Chlamydia infections. The recombinant sequence encoding MOMP multi-epitopes was tandemly inserted and engaged downstream of HPV 6b L1 to construct a plasmid vaccine. COS-7 cells were transfected with pcDNA3.1(+)/Ct MOMP 168 encoding the Ct MOMP multi-epitope gene and co-expressed with the nucleic vaccine plasmid pcDNA3.1(+)/HPV 6b L1/Ct MOMP 168, which contains both the HPV 6b L1 and Ct MOMP multi-epitope genes. In addition, BALB/ c mice were inoculated intramuscularly (i.m.) with pcDNA3.1(+)/HPV 6b L1/Ct MOMP 168 or pcDNA3.1(+)/Ct MOMP 168. Serum IgG and secretory IgA (sIgA) in vaginal washes were then measured. The expression of HPV 6b L1/Ct MOMP multi-epitope was confirmed by western blotting, confocal microscopy and RT-PCR. Mice vaccinated with pcDNA3.1(+)/HPV 6b L1/Ct MOMP 168 had significantly higher IgG and sIgA antibody titers than pcDNA3.1(+)/Ct MOMP 16 controls. The results show that genetic fusion of the molecular adjuvant HPV 6b L1 to Ct MOMP 168 significantly increases the antigen-specific antibody response induced by the Ct MOMP 168 DNA vaccine.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.